VivoSeq
Infectious Disease

HIV Pre-Exposure Prophylaxis

1

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

HIV Pre-Exposure Prophylaxis is an early-stage landscape with 1 program across 1 company. The most active players are Gilead. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Lenacapavir

Gilead

Approved
No programs

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Active, not recruiting2 · 22%
Unknown status1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
Active, not recruiting·UUniversity of California, San Diego·Phase 4·NCT04616963·64 enrolled
A Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People With an Indication for PrEP
Active, not recruiting·Gilead logoGilead·Phase 3·NCT07047716·339 enrolled
PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence
Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT07335289·400 enrolled
HIV Pre-exposure Prophylaxis Implementation Hong Kong Study
Completed·—·N/A·NCT04367688·339 enrolled
Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers
Completed·IIndiana University·Phase 1·NCT03202511·15 enrolled
A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women
Completed·UUniversity of Nebraska·Phase 1·NCT03270969·15 enrolled
Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities
Completed·EEmory University·Phase 1·NCT02985996·48 enrolled
Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand
Completed·Centers for Disease Control and Prevention·Phase 2/3·NCT00119106·2,413 enrolled
HIV Pre-exposure Prophylaxis Implementation Study in South Korea
Unknown status·YYonsei University·N/A·NCT04583267·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)